Oct 5 Drugmaker Insmed Inc said it on Wednesday it had bought the rights to an experimental early-stage respiratory drug from Britain's AstraZeneca Plc in a deal worth $150 million.
AstraZeneca will get $30 million in upfront fees and $120 million in various milestone payments, Insmed said.
The deal adds AstraZeneca's AZD7986 compound to Insmed's pipeline. AZD7986 is designed to stop an enzyme that regulates inflammation in the respiratory system.
Insmed, which focuses on developing treatments for respiratory diseases, said it would start a mid-stage study of the drug in non-cystic fibrosis bronchiectasis, a disease in which the airways in the lungs become permanently dilated due to chronic inflammation and infection. (Reporting by Vidya L Nathan in Bengaluru; Editing by Ted Kerr)
One dead in ENI Congo oil platform fire
BRAZZAVILLE, Dec 3 One person was killed in a fire on an oil platform operated by ENI Congo off the coast of the Congo Republic city of Pointe-Noire, the government said.
Aixtron, Fujian to explore what is left of deal after U.S. veto
FRANKFURT, Dec 3 German semiconductor equipment maker Aixtron will explore with its Chinese suitor what can be salvaged of the planned takeover after a U.S. presidential order ruled the deal posed a national security risk, the company said on Saturday.